<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: &lt;i&gt;PALB2&lt;/i&gt;</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: <i>PALB2</i></h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: <i>PALB2</i></div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Beth N Peshkin, MS, CGC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Claudine Isaacs, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold J Burstein, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne Slavotinek, MBBS, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 17, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1032769193"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph summarizes the interpretation of germline testing of the<em> PALB2 </em>gene. It does <strong>not</strong> discuss indications for testing and is not intended to replace clinical judgment in the decision to test or in the clinical care of the individual who was tested. These subjects are discussed separately [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H1420285353"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H3768560929"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>An approach to reviewing a genetic test report is summarized in the checklist  (<a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">table 1</a>). </p><p>Testing involves two steps by the laboratory: determining the genotype and interpreting the pathogenicity of the variant(s). </p><p>The pathogenicity of each variant is classified by the laboratory into one of five categories  (<a class="graphic graphic_table graphicRef122646" href="/z/d/graphic/122646.html" rel="external">table 2</a>), using information available at the time [<a href="#rid2">2</a>]. </p><p class="headingAnchor" id="H1199045253"><span class="h2">Classification of variants</span><span class="headingEndMark"> — </span>The classification for many variants such as those deemed "likely pathogenic" or a "variant of uncertain significance" (VUS) is periodically updated as more data become available [<a href="#rid3">3</a>]. The uncertainty reflects the available research rather than the accuracy of genotyping.</p><p>If there is concern about the classification, such as for a VUS or low-penetrance variant, obtain an updated interpretation periodically (eg, annually), when clinical management or reproductive decisions might be altered, or if relatives present for genetic testing. </p><p>This can be done by checking a database such as <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fclinvar%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trzGy12ipcVcj41059JRLkL3&amp;TOPIC_ID=132469" target="_blank">ClinVar</a>, contacting the laboratory, or consulting a specialist, clinical geneticist or genetic counselor (see <a class="local">'Locating a genetics expert'</a> below); there is no gold standard approach. Some laboratories routinely provide updates and others provide more information only when requested. Many VUSs are reclassified as benign. Likely benign and benign variants are not routinely reported.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genotype</strong> – Identifies the variants in the gene(s) tested. If the results were obtained by direct-to-consumer testing or a research study, testing should be repeated, possibly in conjunction with additional gene tests, in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (or other nationally certified laboratory). This is particularly true if test results would impact clinical care of the patient and/or their relatives (eg, pathogenic variant identified in a gene with known clinical significance/potential clinical actionability; negative finding in an individual with a suspected cancer syndrome or whose at-risk relative is known to carry a pathogenic variant).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – Determines pathogenicity of the variant(s) identified and presents a classification of such based on standard criteria. May require updating, particularly for VUS, as new research and data are available. (See <a class="local">'Variant of uncertain significance'</a> below.)</p><p></p><p>The table provides a glossary of genetic testing terms  (<a class="graphic graphic_table graphicRef122429" href="/z/d/graphic/122429.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H3057196962"><span class="h2">Disease associations and inheritance</span><span class="headingEndMark"> — </span>Partner and localizer of BRCA2 (<em>PALB2</em>) is a cancer susceptibility gene that encodes a BRCA2-interacting protein [<a href="#rid4">4</a>]. The BRCA2-PALB2 interaction is crucial for key BRCA2 DNA damage response functions as well as tumor suppressor activity. </p><p><em>PALB2</em> is considered a moderate- to high-risk cancer gene. Inheritance is autosomal dominant with incomplete penetrance. Heterozygosity for a pathogenic or likely pathogenic variant in <em>PALB2</em> is associated with increased lifetime risk for several cancers, but many individuals will not develop cancer [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Breast cancer (female) – Absolute risk 41 to 60 percent </p><p class="bulletIndent1"><span class="glyph">●</span>Pancreatic cancer (exocrine) – Absolute risk 5 to 10 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Ovarian cancer – Absolute risk 3 to 5 percent</p><p></p><p>While the risks for breast and pancreatic cancer are relatively well established, risks for the other types of cancers (and breast cancer in males) are not confirmed and/or are difficult to quantify. Other genetic and environmental factors may contribute to overall risk. (See  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes", section on 'PALB2'</a> and  <a class="medical medical_review" href="/z/d/html/83943.html" rel="external">"Familial risk factors for pancreatic cancer and screening of high-risk patients", section on 'Hereditary breast cancer: BRCA and PALB2'</a>.)</p><p>Although rare, biallelic pathogenic variants in <em>PALB2</em> (one pathogenic variant inherited from each parent) are associated with Fanconi anemia. This is an autosomal recessive condition. (See  <a class="medical medical_review" href="/z/d/html/109795.html" rel="external">"Clinical manifestations and diagnosis of Fanconi anemia", section on 'Genetics'</a>.)</p><p class="headingAnchor" id="H2045643237"><span class="h1">INDIVIDUALS WITHOUT CANCER</span></p><p class="headingAnchor" id="H1868559748"><span class="h2">Pathogenic or likely pathogenic variant</span><span class="headingEndMark"> — </span>We treat all variants in <em>PALB2</em> that are pathogenic or likely pathogenic the same for purposes of counseling and cancer risk management, regardless of the initial reason for testing. The risk of breast and ovarian cancer in <em>PALB2</em> carriers appears to be higher in females who have first-degree relatives affected with these cancers. Therefore, risk estimation should consider the family history. In the future, polygenic risk scores may be used to further individualize cancer risk predictions [<a href="#rid6">6</a>]. </p><p>Discussion should include the range of cancer risks, possible interventions for surveillance or risk reduction, and implications for first-degree and more distant relatives (see <a class="local">'At-risk relatives'</a> below). The discussion of risks is individualized based on the person's age and, possibly, family history of cancer. </p><p>Counseling may require additional visits or referral to a genetic counselor, clinical geneticist, or oncologist. Acting upon genetic test results is usually not an emergency; the individual can be reassured that management decisions can be deferred until questions have been answered.</p><p>We adhere to the National Comprehensive Cancer Network (NCCN) recommendations for surveillance and risk reduction [<a href="#rid5">5</a>]. The type of cancer and age of onset in a family member may also inform risk assessment and screening (eg, screening at an earlier age if a family member has an earlier age of onset). </p><p>Several evaluations and interventions can reduce the risk of <em>PALB2</em>-associated cancers. Use of these strategies depends on the patient's age, values, and preferences  (<a class="graphic graphic_algorithm graphicRef134186" href="/z/d/graphic/134186.html" rel="external">algorithm 1</a>). </p><p class="headingAnchor" id="H4208037842"><span class="h3">Interventions for cancer screening or risk reduction</span></p><p class="headingAnchor" id="H2420819224"><span class="h4">Female breast cancer</span></p><p class="bulletIndent1"><span class="glyph">●</span>Increased surveillance:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Annual breast magnetic resonance imaging (MRI) with contrast starting at age 30 years.</p><p class="bulletIndent2"><span class="glyph">•</span>Annual mammography with consideration of tomosynthesis starting at age 30 years.</p><p class="bulletIndent2"><span class="glyph">•</span>Individualized management after age 75 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discussion of risk-reducing bilateral mastectomy, with shared decision-making [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no data about efficacy of hormonal chemoprevention (<a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> or aromatase inhibitor); moreover, studies have found that there is an increased risk of triple-negative breast cancer in <em>PALB2</em> carriers. Therefore, the benefits of this approach are unknown in <em>PALB2</em> carriers. </p><p></p><p class="headingAnchor" id="H2719775868"><span class="h4">Ovarian cancer</span></p><p class="bulletIndent1"><span class="glyph">●</span>Discussion of risk-reducing bilateral salpingo-oophorectomy (rrBSO) for individuals with a family history of ovarian cancer, particularly in first-degree relatives. Surgery can occur after menopause unless there is a family history of premenopausal ovarian cancer. (See  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes", section on 'PALB2'</a>.)</p><p></p><p class="headingAnchor" id="H1861080734"><span class="h4">Pancreatic cancer</span></p><p class="bulletIndent1"><span class="glyph">●</span>Discussion of screening for those with a family history of pancreatic cancer in a first- or second-degree relative on the same side of the family as the pathogenic variant. Usually, this is done by contrast-enhanced MRI/magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic ultrasound (EUS). (See  <a class="medical medical_review" href="/z/d/html/83943.html" rel="external">"Familial risk factors for pancreatic cancer and screening of high-risk patients", section on 'Screening modality and timing'</a>.)</p><p></p><p class="headingAnchor" id="H2930839439"><span class="h2">Negative test</span><span class="headingEndMark"> — </span>Negative testing means no pathogenic variants were identified. </p><p class="bulletIndent1"><span class="glyph">●</span>If a familial <em>PALB2</em> pathogenic variant is identified and the tested individual does not have that variant, usually they can be reassured that they are unlikely to be at high risk for <em>PALB2</em>-associated cancers, with the caveats outlined above. (See <a class="local">'How to read the report'</a> above.)</p><p></p><p class="bulletIndent1">However, it is important to assess family history, including family history on the side of the family without t<em>he PALB2</em> pathogenic variant, as well as other personal cancer risk factors to provide an individualized risk assessment. As with variants in other genes in which the risk assessment is particularly dependent on family history, relatives who test negative for the familial pathogenic variant may not have cancer risks that are reduced to the level of the general population [<a href="#rid8">8,9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a familial variant in <em>PALB2</em> is not known and results of genetic testing are negative, additional risk factors for cancer (hereditary or acquired) may be present, and comprehensive testing with a cancer gene panel may be recommended. Surveillance and risk reduction recommendations are based on personal risk factors and family history. Referral to a clinical geneticist, oncologist, or genetic counselor may be helpful to determine optimal testing in those with a strong or suggestive family history of cancer. (See <a class="local">'Locating a genetics expert'</a> below.) </p><p></p><p class="headingAnchor" id="H3737032256"><span class="h2">Variant of uncertain significance</span><span class="headingEndMark"> — </span>Individuals with a variant of uncertain significance (VUS) should be managed based on their personal and family history and not the VUS  (<a class="graphic graphic_algorithm graphicRef134186" href="/z/d/graphic/134186.html" rel="external">algorithm 1</a>).</p><p>New information may become available, and the testing laboratory or other resource should be consulted periodically for updates in the classification (eg, annually). (See <a class="local">'Classification of variants'</a> above.)</p><p class="headingAnchor" id="H2668044579"><span class="h1">INDIVIDUALS WITH CANCER</span><span class="headingEndMark"> — </span>The implications of genetic test results should be discussed with the individual's oncologist or surgeon; in some cases, referral to a specialist in cancer genetics may be appropriate. </p><p>A pathogenic or likely pathogenic variant in <em>PALB2 </em>may impact cancer therapy, surveillance, and risk reduction:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemotherapy </strong>– In general, the choice of chemotherapy is not affected by <em>PALB2</em> status, although some studies suggest that DNA-damaging agents, such as platinum-based chemotherapy, may be particularly effective in <em>PALB2</em> carriers. Additionally, individuals with germline <em>PALB2</em> pathogenic variants may be candidates for treatment with poly(ADP-ribose) polymerase (PARP) inhibitors. (See  <a class="medical medical_review" href="/z/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'Special considerations'</a> and  <a class="medical medical_review" href="/z/d/html/2475.html" rel="external">"Initial systemic chemotherapy for metastatic exocrine pancreatic cancer", section on 'Initial treatment'</a> and  <a class="medical medical_review" href="/z/d/html/128308.html" rel="external">"Management of advanced prostate cancer with germline or somatic homologous recombination repair deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery</strong> – A female with breast cancer may seek bilateral mastectomy to reduce the risk of second primary breast cancer. However, the risk of contralateral breast cancer is not well established. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance and risk reduction</strong> – Additional measures may be warranted, particularly for ovarian cancer. (See <a class="local">'Pathogenic or likely pathogenic variant'</a> above.)</p><p></p><p>Genetic counseling and testing of adult first- and second-degree relatives are also appropriate. (See <a class="local">'Considerations for relatives'</a> below.)</p><p>Further discussion of cancer risks associated with <em>PALB2</em>-pathogenic variants is presented separately. (See  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes", section on 'PALB2'</a>.)</p><p>For individuals with negative genetic testing or a variant of uncertain significance (VUS) for whom there are reasons to be concerned about a hereditary cause, additional genetic testing may be appropriate based on personal and family history of cancer. The need for additional testing may be discussed with a genetic counselor, clinical geneticist, or the primary oncologist, or other specialists with expertise in managing hereditary cancer syndromes. (See <a class="local">'Locating a genetics expert'</a> below.)</p><p class="headingAnchor" id="H2352443384"><span class="h1">CONSIDERATIONS FOR RELATIVES</span></p><p class="headingAnchor" id="H2496520419"><span class="h2">Reproductive counseling</span><span class="headingEndMark"> — </span>Reproductive counseling (ideally done prior to conception) is appropriate for individuals with a pathogenic or likely pathogenic variant in <em>PALB2</em> who are considering childbearing or may wish to have children in the future.</p><p>Some may elect to conceive using donor gametes or in vitro fertilization (IVF) with preimplantation genetic testing (PGT) or prenatal diagnosis. (See  <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">"Preimplantation genetic testing", section on 'Patients known to be at increased risk of offspring with a specific medically actionable condition'</a>.) </p><p class="headingAnchor" id="H3397463752"><span class="h2">At-risk relatives</span><span class="headingEndMark"> — </span>Individuals who test positive for a pathogenic or likely pathogenic variant should inform their relatives about the importance of genetic counseling and the option of genetic testing.</p><p class="bulletIndent1"><span class="glyph">●</span>The risk of having inherited or having the variant is 50 percent for first-degree relatives (parents, siblings, children). Other at-risk relatives may include aunts, uncles, nieces, nephews, and cousins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because it is very rare for <em>PALB2-</em>associated cancers to occur before adulthood, genetic testing is generally deferred until ≥18 years to allow for informed consent. (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing", section on 'Ethical, legal, and psychosocial issues'</a>.)</p><p></p><p class="headingAnchor" id="H3996120069"><span class="h1">RESOURCES</span></p><p class="headingAnchor" id="H1856845902"><span class="h2">UpToDate topics</span></p><p class="bulletIndent1"><span class="glyph">●</span><em>PALB2</em>-associated cancers:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cancer risks – (See  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes", section on 'PALB2'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic testing – (See  <a class="medical medical_review" href="/z/d/html/753.html" rel="external">"Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Breast cancer – (See  <a class="medical medical_review" href="/z/d/html/792.html" rel="external">"Factors that modify breast cancer risk in women"</a> and  <a class="medical medical_review" href="/z/d/html/14227.html" rel="external">"ER/PR negative, HER2-negative (triple-negative) breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/94744.html" rel="external">"Contralateral prophylactic mastectomy"</a> and  <a class="medical medical_review" href="/z/d/html/779.html" rel="external">"Breast cancer in men"</a> and  <a class="medical medical_review" href="/z/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Pancreatic cancer – (See  <a class="medical medical_review" href="/z/d/html/83943.html" rel="external">"Familial risk factors for pancreatic cancer and screening of high-risk patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Variant classification – (See  <a class="medical medical_review" href="/z/d/html/96539.html" rel="external">"Secondary findings from genetic testing", section on 'Definitions and classification of variants'</a>.) </p><p class="bulletIndent2"><span class="glyph">•</span>Terminology – (See  <a class="medical medical_review" href="/z/d/html/2898.html" rel="external">"Genetics: Glossary of terms"</a>.)</p><p></p><p class="headingAnchor" id="H1213770543"><span class="h2">Locating a genetics expert</span></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical geneticists – American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=132469" target="_blank">ACMG</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic counselors – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=132469" target="_blank">NSGC</a>)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li><a class="nounderline abstract_t">Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405.</a></li><li><a class="nounderline abstract_t">Mighton C, Charames GS, Wang M, et al. Variant classification changes over time in BRCA1 and BRCA2. Genet Med 2019; 21:2248.</a></li><li><a class="nounderline abstract_t">Tischkowitz M, Balmaña J, Foulkes WD, et al. Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2021; 23:1416.</a></li><li class="breakAll">Genetic/familial high-risk assessment: colorectal 2.2022. NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf (Accessed on March 21, 2023).</li><li><a class="nounderline abstract_t">Gallagher S, Hughes E, Wagner S, et al. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. JAMA Netw Open 2020; 3:e208501.</a></li><li><a class="nounderline abstract_t">Hartmann LC, Lindor NM. The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. N Engl J Med 2016; 374:454.</a></li><li><a class="nounderline abstract_t">Lee AJ, Cunningham AP, Tischkowitz M, et al. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genet Med 2016; 18:1190.</a></li><li><a class="nounderline abstract_t">Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 2016; 13:581.</a></li></ol></div><div id="topicVersionRevision">Topic 132469 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25741868" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30971832" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Variant classification changes over time in BRCA1 and BRCA2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33976419" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33976419" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32609350" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26840135" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27464310" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27296296" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Counselling framework for moderate-penetrance cancer-susceptibility mutations.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
